Biblio
Export 1647 results:
Author [ Title] Type Year Filters: First Letter Of Last Name is C [Clear All Filters]
“Use of Immersive Virtual Reality in the Assessment and Treatment of Alzheimer's Disease: A Systematic Review.”, J Alzheimers Dis, vol. 75, no. 1, pp. 23-43, 2020.
, “Use of Immersive Virtual Reality in the Assessment and Treatment of Alzheimer's Disease: A Systematic Review.”, J Alzheimers Dis, vol. 75, no. 1, pp. 23-43, 2020.
, “Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort.”, J Alzheimers Dis, vol. 58, no. 2, pp. 435-448, 2017.
, “Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 60, no. 1, pp. 87-95, 2017.
, “Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 60, no. 1, pp. 87-95, 2017.
, “Urban Air Pollution Nanoparticles from Los Angeles: Recently Decreased Neurotoxicity.”, J Alzheimers Dis, vol. 82, no. 1, pp. 307-316, 2021.
, “Upregulation of Local Hepcidin Contributes to Iron Accumulation in Alzheimer's Disease Brains.”, J Alzheimers Dis, vol. 82, no. 4, 2021.
, “Upregulation of Cortical A2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 1105-1117, 2021.
, “Upregulation of Cortical A2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 1105-1117, 2021.
, “Upregulation of Connexin 43 Expression Via C-Jun N-Terminal Kinase Signaling in Prion Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1005-19, 2016.
, “Upregulation of Connexin 43 Expression Via C-Jun N-Terminal Kinase Signaling in Prion Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1005-19, 2016.
, “Upregulation of Connexin 43 Expression Via C-Jun N-Terminal Kinase Signaling in Prion Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1005-19, 2016.
, “Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer's Disease.”, J Alzheimers Dis, vol. 58, no. 1, pp. 185-192, 2017.
, “Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer's Disease.”, J Alzheimers Dis, vol. 58, no. 1, pp. 185-192, 2017.
, “Unusual Clinical Presentations Challenging the Early Clinical Diagnosis of Creutzfeldt-Jakob Disease.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1051-1065, 2018.
, “Unstable Body Mass Index and Progression to Probable Alzheimer's Disease Dementia in Patients with Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 2, pp. 483-91, 2016.
, “Understanding Epigenetics in the Neurodegeneration of Alzheimer's Disease: SAMP8 Mouse Model.”, J Alzheimers Dis, vol. 62, no. 3, pp. 943-963, 2018.
, “An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults.”, J Alzheimers Dis, vol. 68, no. 3, pp. 1161-1170, 2019.
, “Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 3, pp. 775-783, 2019.
, “Ubisol-Q10 (a Nanomicellar Water-Soluble Formulation of CoQ10) Treatment Inhibits Alzheimer-Type Behavioral and Pathological Symptoms in a Double Transgenic Mouse (TgAPEswe, PSEN1dE9) Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 221-236, 2018.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Two Novel Mutations in the First Transmembrane Domain of Presenilin1 Cause Young-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 58, no. 4, pp. 1035-1041, 2017.
,